Ezetimibe labeling updated to include additional safety information

The product label for ezetimibe (Zetia, Merck/Schering-Plough) has been revised to include hypersensitivity reactions, including rash and angioedema, as part of the adverse reactions section, according to Schering-Plough. The companies submitted an updated product label to FDA in April based on post-marketing surveillance, and the new label entered the market in July.